T cell activation following infection of primary follicle center lymphoma B cells with adenovirus encoding CD154

被引:17
作者
Cantwell, MJ
Wierda, WG
Lossos, IS
Levy, R
Kipps, TJ
机构
[1] Univ Calif San Diego, Dept Med, Div Hematol Oncol, Sch Med, La Jolla, CA 92093 USA
[2] Stanford Univ, Sch Med, Div Oncol, Stanford, CA 94305 USA
[3] Immunogenex Inc, La Jolla, CA USA
关键词
follicle center lymphoma; CD154; adenovirus;
D O I
10.1038/sj.leu.2402208
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purified, high-titer adenovirus encoding murine CD154 (Ad-CD154) or human CD154 (Ad-hCD154) was used to infect lymph node cells isolated from patients with follicle center lymphoma. Infection of lymphoma B cells with Ad-CD154 at a multiplicity of infection (MOI) ratio of 100 or higher resulted in high-level transgene expression. Additionally, upon infection of lymphoma B cells, only Ad-CD154 resulted in surface expression of CD154, despite similar, high-level expression of either human or mouse CD154 by HeLa cells infected with Ad-hCD154 or Ad-CD154, respectively. Moreover, infection of lymphoma B cells with Ad-CD154, but not Ad-hCD154 or adenovirus encoding Eschericheria coli beta-galactosidase (Ad-LacZ), induced the neoplastic B cells to express higher levels of immune costimulatory molecules that are required for proficient presentation of antigen to T cells. Consistent with this, we found that Ad-CD154 infected lymphoma B cells could stimulate T cells to proliferate or produce interferon-gamma in allogeneic or autologous mixed lymphocyte interactions. We conclude that lymphoma B cells can be infected with Ad-CD154 and that this significantly enhances their recognition by allogeneic or autologous T cells. As such, Ad-CD154-transduced lymphoma B cells may have potential for the active immune therapy of patients with follicle center lymphoma.
引用
收藏
页码:1451 / 1457
页数:7
相关论文
共 35 条
[1]  
Andersen NS, 2000, BLOOD, V96, P2219
[2]   THE CD40 LIGAND, GP39, IS DEFECTIVE IN ACTIVATED T-CELLS FROM PATIENTS WITH X-LINKED HYPER-IGM SYNDROME [J].
ARUFFO, A ;
FARRINGTON, M ;
HOLLENBAUGH, D ;
LI, X ;
MILATOVICH, A ;
NONOYAMA, S ;
BAJORATH, J ;
GROSMAIRE, LS ;
STENKAMP, R ;
NEUBAUER, M ;
ROBERTS, RL ;
NOELLE, RJ ;
LEDBETTER, JA ;
FRANCKE, U ;
OCHS, HD .
CELL, 1993, 72 (02) :291-300
[3]   THE CD40 ANTIGEN AND ITS LIGAND [J].
BANCHEREAU, J ;
BAZAN, F ;
BLANCHARD, D ;
BRIERE, F ;
GALIZZI, JP ;
VANKOOTEN, C ;
LIU, YJ ;
ROUSSET, F ;
SAELAND, S .
ANNUAL REVIEW OF IMMUNOLOGY, 1994, 12 :881-922
[4]  
BECKER TC, 1994, METHOD CELL BIOL, V43, P161
[5]   An improved anion-exchange HPLC method for the detection and purification of adenoviral particles [J].
Blanche, F ;
Cameron, B ;
Barbot, A ;
Ferrero, L ;
Guillemin, T ;
Guyot, S ;
Somarriba, S ;
Bisch, D .
GENE THERAPY, 2000, 7 (12) :1055-1062
[6]  
Blossom S, 1997, J IMMUNOL, V159, P4580
[7]   Acquired CD40-ligand deficiency in chronic lymphocytic leukemia [J].
Cantwell, M ;
Hua, T ;
Pappas, J ;
Kipps, TJ .
NATURE MEDICINE, 1997, 3 (09) :984-989
[8]   Adenovirus vector infection of chronic lymphocytic leukemia B cells [J].
Cantwell, MJ ;
Sharma, S ;
Friedmann, T ;
Kipps, TJ .
BLOOD, 1996, 88 (12) :4676-4683
[9]  
CASTLE BE, 1993, J IMMUNOL, V151, P1777
[10]   Coexpression of CD40 and CD40 ligand in B-cell lymphoma cells [J].
Clodi, K ;
Asgary, Z ;
Zhao, SR ;
Kliche, KO ;
Cabanillas, F ;
Andreeff, M ;
Youns, A .
BRITISH JOURNAL OF HAEMATOLOGY, 1998, 103 (01) :270-275